GSK CEO and CFO Interviewed on 2014 Q3 Results

LONDON, October 22, 2014 /PRNewswire/ --

Amid continued pricing pressure in the Respiratory business, Sir Andrew Witty, CEO, has announced a restructuring of the pharmaceutical business. In a video interview he said:

"What we've seen and we can identify are a number of opportunities to significantly reduce the cost structure of the organisation."

Witty goes on to say that the company is considering a possible partial IPO of the ViiV business.

Simon Dingemans, CFO, said GSK was seeing "significant price pressure, which has led to overall US sales down 10% for the quarter". However, he adds that this should not obscure the broader geographies and businesses contributing to performance such as Emerging Markets, Japan, and ViiV, as well as an increasingly important contribution from new products.

The video interviews and transcript are available now on http://video.merchantcantos.com/companies/g/glaxosmithkline/.

MerchantCantos produces Executive Interviews, Investor Documentaries and Webcasts with senior management. If you would like to contact us, please email [email protected] or phone +44-207-936-1352.

The interview and transcript are available now on http://www.cantos.com.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-207-936-1352.

SOURCE GlaxoSmithKline

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.